At right, please find a listing of active clinical trials and links to additional trial protocol information for these studies as posted on the National Instiutes of Health (NIH) clinical trials website.

For general information on clinical trials, terms related to clinical trials and other general health information, please visit the NIH website.

CAL-101 – HEMATOLOGIC MALIGNANCIES
More information about ongoing trials can be found at clinicaltrials.gov

A Study of CAL-101 and Rituximab in Elderly Patients With Untreated CLL or SLL

A Phase 2 Single Arm Study to Investigate the Safety and Clinical Activity of CAL-101 in Combination With Rituximab in Elderly Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. More info on clinicaltrials.gov

Dose-Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies

A Phase 1 trial evaluating CAL-101 safety and clinical activity in patients with hematologic malignances is currently enrolling. The dose escalation phase is complete, and cohort expansion is underway in patients with relapsed or refractory acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), Aggressive non-Hodgkin’s lymphoma (NHL) and Indolent NHL. More info on clinicaltrials.gov

Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

A Phase 1 long-term safety extension study of CAL-101 in patients with hematologic malignancies to allow patients who derive clinical benefit at the end of the 12-month treatment period in standard CAL-101 protocols to continue on CAL-101 treatment until disease progression. More info on clinicaltrials.gov

Study to Investigate CAL-101 in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

The open-label, multicenter trial in patients with non-Hodgkin’s lymphoma and chronic lymphocytic leukemia to evaluate the safety and efficacy of CAL-101 in three different regimens: CAL-101 plus rituximab, CA-101 plus bendamustine, and CAL-101 plus rituximab and bendamustine. More info on clinicaltrials.gov

CAL-101 is currently being investigated in clinical trials and has not received U.S. F.D.A. approval. Calistoga Pharmaceuticals does not claim that this technology or any of its product candidates are safe or will be effective in preventing, treating or curing any disease or condition.


        

    

    
    



	





Recommended Websites